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Although anecdotal reports showing the uncommon associa- 
tion of aplastic anaemia (AA) and lymphoma have been pub- 
lished (Dorr et al, 1996; Koziner et al, 1975; Medinger et al, 
2012; Suzuki et al, 2009; Veidt et al, 2005; Yoshioka et al, 
1999; Zonder et al, 2002), data related to its incidence, diag- 
nostic characteristics and centre management strategies are 
lacking. The Severe Aplastic Anaemia Working Party of the 
European Society of Blood and Bone Marrow Transplanta- 
tion (SAAWP-EBMT) aimed to evaluate the diseases charac- 
teristics and treating centre attitudes regarding the treatment 
and outcome of patients suffering from both AA and lym- 
phoma. Between 2013–2015, we collected data of patients 
with this combination. Congenital bone marrow failures, as 
well as AA or lymphoma that occurred after haematopoietic 
stem cell transplantation (HSCT) were excluded. 
Eighty-three  (28%)  of  the  294  EBMT  centres  contacted 
participated in this study; 13 (16%) centres, from 7 differ-    
ent countries, reported the 26 cases  included  in  the  study. 
AA was diagnosed between 1983–2015; median age at AA 
diagnosis was 57 (10–78) years, 16 patients (62%)  were  
male, 13 patients had severe AA (SAA) and 6 very severe    
AA (vSAA). Of the 18 cases investigated for paroxysmal 
nocturnal haemoglobinuria (PNH) clones by flow  cytome-  
try, two had a small clone, without clinical PNH signs or 
symptoms. Cytogenetics was available in 22/26(85%) cases; 
only one had an anomaly (trisomy 12). At  AA  diagnosis,  
85% and 86% of patients required red  blood cell and plate-  
let transfusions, respectively. Lymphoma was diagnosed 
between 1958 and 2015, at a median age  of  52 years  (12–
78). Five patients (19%) had Hodgkin lymphoma (HL)  for 
which histopathology was available in 4 cases: 2 lym- phocyte 
predominant type, 1 nodular sclerosis and 1 mixed cellularity.  
Non-Hodgkin  lymphoma  (NHL)  was  reported in 
21 (81%) patients: 19 (73%) had a B-cell NHL and two 
patients an unspecified lymphoma. A  subtype  of  B-cell  
NHL was reported in 18 cases: 4 diffuse large B-cell, 3 lym- 
phoplasmacytic, 3 follicular, 3 nodal marginal  zone,  2 
chronic lymphocytic leukaemia, 1 splenic marginal zone, 1 
mantle cell and 1 plasma cell neoplasm. The lymphoma was 
treated in 23 cases (91%). 
Lymphoma was detected at three different times with 
respect to AA (Fig 1): 11 patients presented with lymphoma 
 
before AA, 7 patients were simultaneously  diagnosed  with 
AA and lymphoma, and 8 patients presented with lymphoma 
after AA diagnosis . 
Patients presenting AA and lymphoma  simultaneously  
were significantly older compared to the other times of pre- 
sentation (Table I). HL was mainly observed in patients 
presenting lymphoma before AA (4 out of 5 HL). Various 
underlying pathogenic mechanisms may be involved in the 
different times of presentation. AA occurring after lym-  
phoma and/or its treatment could have a different cause of 
marrow failure than typical AA. Alkylating  agents included  
in lymphoma therapy, could lead to exhaustion of the stem  
cell  pool,  resulting  in  subsequent  marrow  failure   (Gobbi 
et al, 2009). In line with this  hypothesis,  we  found  that  
more patients with AA occurring after lymphoma failed to 
respond to standard immunosuppressive therapy (IST) and 
needed a HSCT (Table I). Likewise, the use of purine 
nucleoside analogues have significant cytotoxic activity, 
resulting in prolonged lymphocyte depletion, especially in 
CD4 T-cells; this immune dysregulation might facilitate 
autoimmunity. In our series, only one patient  was  treated  
with fludarabine before the development of AA. When AA 
and lymphoma occur concomitantly, AA may emerge as a 
paraneoplastic autoimmune phenomenon of the lymphoma 
(Chandor, 1988), although our data could not fully confirm 
this hypothesis. In 3 of the 7 cases with concomitant pre- 
sentation, the lymphoma was treated first, aiming to control 
both diseases; however, after chemotherapy, complete remis- 
sion of the lymphoma was achieved in 2 of these cases but   
the AA did not respond and needed subsequently therapy. 
Furthermore, lymphoma has been reported following 
administration of  anti-thymocyte  globulin  (ATG)  (Calistri  
et al, 2006). In this series, lymphoma was diagnosed in 2 
patients within one year  after ATG therapy; in  both cases,  
the AA remained active at lymphoma diagnosis (1 partial 
response, 1 non-responder). In this study, none  of  the 
reported lymphomas were Epstein–Barr virus associated. All 
these pathophysiological hypotheses concerning the associa- 
tion of AA and lymphoma are conceivable, but need to be 
proven. 
In patients where AA appeared first, the standard AA 
approach for therapy was observed, thus all patients received 
  
 
 
 
Fig 1. Order of lymphoma appearance with regard to aplastic anaemia. AA, aplastic anaemia; HL, Hodgkin lymphoma; NHL, non-Hodgkin 
lymphoma; SAA, severe aplastic anaemia; vSAA, very severe aplastic anaemia. 
 
 
ATG. The absence of HSCT as first line treatment is  
explained by the exclusion criteria of this study. The manage- 
ment of AA was more heterogeneous when both diseases 
appeared simultaneously or when AA occurred after lym- 
phoma. When presentation was concomitant, although  6 of 
the 7 patients had SAA or vSAA, only 1 patient received a 
standard IST including ATG. In 3 cases the lymphoma was 
treated first, and 2 cases received treatment including other 
drugs, such as alemtuzumab and steroids, aiming to simulta- 
neously treat both diseases. The centres reported that therapy 
was oriented to treat the more severe, or symptomatic dis- 
ease. When AA occurred after the lymphoma, the manage- 
ment approach was also heterogeneous,  including  one  
patient who received HSCT as first line therapy. 
Patients’ outcome analysis showed that 17 (65%) patients 
were alive at last follow-up. The 9 deaths included 6 due to  
AA (either from the disease itself or HSCT-related cause), 1 
after HSCT to treat the lymphoma; 1 from a second malig- 
nancy and 1 due to advanced age. AA-related causes  of  
deaths were significantly more frequent than lymphoma- 
related deaths (P < 0·001). 
The presented data do not enable clear recommendations   
to be made regarding the management of AA when associ- 
ated with lymphoma. However, centre preferences can be 
discussed. When AA presents first, it is clear that AA has to  
be treated according to its severity following the standard of 
care. The appearance of lymphoma later in the course does  
not seem to affect the prognosis. The decision to treat AA is 
more controversial when lymphoma appears before or at the 
same time as AA. Given that the outcome of AA seems to 
prevail over that of lymphoma, patients should receive, 
whenever possible, standard treatment for AA. Given there is  
a probability of stem cell exhaustion after lymphoma treat- 
ment (such cases will never respond to IST), an allogeneic 
HSCT should be considered and, if indicated, a search of a 
stem cell donor initiated. 
In conclusion, the combination of AA and lymphoma is a 
rare and heterogeneous event, in which the  outcome  is  
mainly affected by the AA rather than the lymphoma. We 
believe that continuing systematic evaluation of such rare 
presentations, together with the recent achievement of 
molecular  aspects  of  both  diseases,  might  contribute  to the 
  
Table I. Association of AA and lymphoma. Comparison of disease presentation, treatment and outcome. 
 
 
 
 
 
 
 
Age at lymphoma, years (range) 46 (12–71) 68 (47–78) 47 (14–70) 0·02 
Age at 1st diagnosis, years (range) 49 (12–73) 68 (47–78) 41 (9–67) 0·01 
Median interval 1st–2nd diagnosis,  in months 15 (3–436) na 45 (4–135) 
AA Severity 
vSAA 3 1 2 
SAA 5 5 3 ns 
Non-severe AA 3 1 1 
Unknown 1 0 2 
Type of lymphoma 
B-cell lymphoma 7 6 6 
HL 4 1 0 0·05 
Unspecified lymphoma 0 0 2 
Treatment 
AA Therapy 
ATG containing 4 1 8  
CSA alone 5 2 0 
G-CSF 1 0 0 0·005 
Alemtuzumab 
HSCT 
0 
1 
1 
0 
0 
0 
 
No treatment 0 3 0  
Response to IST     
Complete response 2 1 3  
Partial response 1 1 3  
No response 8 1 2  
Unknown 0 1 0  
First line therapy of lymphoma     
CHOP-line/HL treatment 6 2 3  
Rituximab 2 2 3  
Steroid alone 1 1 0 ns 
Radiotherapy 1 0 0  
No treatment 0 2 0  
unknown 1 0 2  
Lymphoma response after therapy     
Complete remission 6 2 2  
Partial remission 1 0 3  
No response 2 3 2  
Unknown 2 0 1  
All HSCT 6 (54%) 2 (29%) 3 (31%) ns 
Indicated for AA 6 1 0 0·01 
Indicated for lymphoma 0 1 3 
Outcome    
Alive 6 (55%) 5 (71%) 6 (75%) 
Death 5 (45%) 2 (29%) 2 (25%) 
Causes of death     
AA and/or its treatment 3 2 1 
Lymphoma and/or its treatment 0 0 1 
Others 2 0 0 
AA, aplastic anaemia; ATG, anti-thymocyte globulin; CHOP, cytoxan, adriamycin, vincristine and prednisone; CSA, ciclosporin; G-CSF, granulo- 
cyte colony-stimulating factor; HL, Hodgkin lymphoma; HSCT, haematopoietic stem cell transplantation;SAA, severe aplastic anaemia; vSAA, very 
severe aplastic anaemia. 
 
Parameters 
Lymphoma 
before AA 
Simultaneous 
Lymphoma and AA 
Lymphoma 
after AA 
 
P 
N 11 7 9 
 
Males 7 (64%) 5 (71%) 4 (50%) ns 
Age at AA, years, (range) 49 (20–73) 68 (47–78) 41 (9–67) 0·02 
 
  
understanding and better management of  these  patients  in  
the future. 
 
Acknowledgements 
We thank all participating centres and data  managers  for  
their valuable contribution in this study. 
Reporting EBMT centres (Centre Identification code: 
country, city, investigator/s, number of patients): 202: 
Switzerland, Basel, Michael Medinger/Jakob Passweg, 4; 205: 
United Kingdom, London, Edward Kanfer, 1; 207: France, 
Paris, Regis Peffault de la Tour, 1; 221: Switzerland, Bern, 
Alicia  Rovo´,  1;  231:  Italy,  Torino,  1;  252:  France,  Creteil, 
Sebastien Maury, 1; 253: France, Nantes, Patrice Chevallier,  
2; 305: Italy, Torino, Paola Quarello, 1; 539: United King- 
dom, London, Mickey Koh, 1; 565: Netherlands, Maastricht, 
Harry Schouten, 1; 590: Germany, Berlin, Wolfgang Blau, 1; 
613: Spain, Barcelona, Jose M Ribera, 2; 763: United King- 
dom, London, Austin Kulasekararaj/Anita Hill, 9. 
 
Authorship contributions 
AR served as the principal investigator for this study; AR; 
RPdeL; AT; ARis; JP; JM and CD contributed to the study 
design. AR; AK; MM; PC; JMR; RPdeL; CK; EK; BB; SM; 
PQ; MBCK; HS; IWB; AT; AH; ARis; JP; JM; PD and CD 
contributed to the data collection. AR; CK; SI; AT and CD 
contributed to data and statistical analysis. AR wrote the 
paper, AK; MM; PC; JMR; RPdeL; CK; SI; EK; BB; SM; PQ; 
MBCK; HS; IWB; AT; AH; ARis; JP; JM; PD and CD revised 
and agreed with this manuscript. 
 
 
Disclosure of conflicts of interest 
The authors have no conflicts of interest to disclose. 
Alicia Rovo´1  
 Austin Kulasekararaj
2 
Michael Medinger3 
Patrice Chevallier4 
Jose M. Ribera5 
Regis Peffault de Latour6  
Cora Knol7 
Simona Iacobelli8 
Edward Kanfer9 
Benedetto Bruno10 
Se´bastien Maury11 
Paola Quarello12 
Mickey B. C. Koh13 
Harry Schouten14 
Igor W.Blau15 
Andre´ Tichelli3 
Anita Hill16 
Antonio Risitano17  
Jakob Passweg3 
Judith Marsh2 
Peter Dreger18 
Carlo Dufour19 
on behalf of the Severe Aplastic Anaemia Working Party  
of the EBMT 
1University Hospital of Bern, Bern, Switzerland, 2King’s Denmark Hill 
Campus, London, UK, 3University Hospital of Basel, Basel, Switzerland, 
4University Medical Centre, Nantes, France, 5Catalan Institute of 
Oncology, Hospital Germans Trias i Pujol, Jose Carreras Research Insti- 
tute, Badalona, Spain, 6Hopital St. Louis, Paris, France, 7EBMT Data 
Office, Leiden, the Netherlands, 8Centro Interdipartimentale di Biosta- 
tistica e Bioinformatica, Universita` Tor Vergata, Rome, Italy, 9Imperial 
College, London, UK, 10A.O.U. Citta della Salute e della Scienza, Tor- 
ino, Italy, 11Ho^pital Henri Mondor, Creteil, France, 12Ospedale Infan- 
tile Regina Margherita, Torino, Italy, 13St. George’s Hospital, London, 
UK, 14University Medical Centre, Maastricht, the Netherlands, 
15Charit´e - Campus Virchow Klinikum, Berlin, Germany, 16Leeds 
Teaching Hospitals, Leeds, UK, 17University of Napoli, Napoli, Italy, 
18University of Heidelberg, Heidelberg, Germany and 19G. Gaslini 
Children’s Hospital, Genova, Italy. 
E-mail: alicia.rovo@insel.ch 
 
Keywords: aplastic anaemia, lymphoma, lymphoid neoplasms, 
haematopoietic stem cell transplantation 
 
 
References 
Calistri, E., Tiribelli, M., Battista, M., Michelutti, 
A., Corbellino, M., Viale, P., Fanin, R. & Dami- 
ani, D. (2006) Epstein-Barr virus reactivation in  
a patient treated with anti-thymocyte  globulin  
for severe aplastic anemia. American Journal of 
Hematology, 81, 355–357. 
Chandor, S.B. (1988) Autoimmune phenomena in 
lymphoid malignancies. Clinics in Laboratory 
Medicine, 8, 373–384. 
Dorr, V., Doolittle, G. & Woodroof, J. (1996) First 
report of a B cell lymphoproliferative disorder 
arising in a patient treated with immune 
 
suppressants for severe aplastic anemia. Ameri- 
can Journal of Hematology, 52, 108–113. 
Gobbi, P.G., Valentino, F., Danova, M., Morabito, 
F., Rovati, B., Mammi, C., Gentile, M., Merli, F., 
Stelitano, C., Luminari, S., Quintana, G., Iannitto, 
E., Brugiatelli, M. & Federico, M. (2009) Bone 
marrow stem cell damage after three different 
chemotherapy regimens for advanced Hodgkin’s 
lymphoma. Oncology Reports, 21, 1029–1035. 
Koziner, B., Ellman, L. & Aisenberg, A.C. (1975) 
Lymphoma presenting as bone marrow failure. 
Cancer, 35, 1426–1429. 
Medinger, M., Buser, A., Stern, M., Heim, D., Hal- 
ter, J., Rovo, A., Tzankov, A., Tichelli, A. & 
 
Passweg, J. (2012) Aplastic anemia in association 
with a lymphoproliferative neoplasm: coinci- 
dence or causality? Leukemia Research, 36, 250– 
251. 
Suzuki, Y., Niitsu, N., Hayama, M., Katayama, T., 
Ishii, R., Osaka, M., Miyazaki, K., Danbara, M., 
Horie, R., Yoshida, T., Nakamura, N. & Higa- 
shihara, M. (2009) Lymphoproliferative disor- 
ders after immunosuppressive therapy for  
aplastic anemia: a case report and literature 
review. Acta Haematologica, 121, 21–26. 
Veidt, R.G., Ansari-Lari, A. & Brodsky, R.A. 
(2005) Severe aplastic anemia associated with 
paroxysmal nocturnal hemoglobinuria and 
  
lymphoplasmacytic lymphoma. Leukaemia & 
Lymphoma, 46, 1243–1246. 
Yoshioka, Y., Kawamata, N., Sato, E., Isobe, Y. & 
Oshimi, K. (1999) Primary splenic lymphoma 
with hypoplastic bone marrow. Rinsho Ketsueki, 
40, 124–128. 
Zonder, J.A., Keating, M. & Schiffer, C.A. (2002) 
Chronic lymphocytic leukemia presenting in 
association with aplastic anemia. American Jour- 
nal of Hematology, 71, 323–327. 
